The key issue for the FTC is whether the deal kills competition between Concert's treatment and Vertex's Kalydeco.
Concert must submit toxicology data to the FDA before proceeding with Phase 2 trials.
This little biotech packed a big wallop on Monday as its stock nearly doubled. Here's why.
Acquiring CTP-656 from Concert Pharmaceuticals will only cost Vertex around $250 million.